Evidence map›Paper›PMID 31182884›Full record

ReviewIranian journal of medical sciences2019

Effectiveness of Paromomycin on Cutaneous Leishmaniasis in Iran: A Systematic Review and Meta-Analysis.

Rahmatollah Moradzadeh, Parvaneh Golmohammadi, Hami Ashraf, Haidar Nadrian, Mohammad Reza Fakoorziba

Open access · greenAbstract readReview
In one paragraph

Review in Iranian journal of medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. The frequency, related cause of disease, and treatment of hepatitis B virus infection: A systematic review and meta-analysis in Iran.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rahmatollah MoradzadehDepartment of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran.
Parvaneh GolmohammadiDepartment of Epidemiology, School of Health, Arak University of Medical Sciences, Arak, Iran.
Hami AshrafRazavi Cancer Research Center, Research and Education Department, Razavi Hospital, Mashhad, Iran.
Haidar NadrianDepartment of Health Education and Promotion. Faculty of Health Sciences, Tabriz University of Medical Sciences, Tabriz. Iran.
Mohammad Reza FakoorzibaDepartment of Medical Entomology and Vector Control, Research Centre for Health Sciences, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Arak University of Medical Sciences · IRShiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSome treatment reported for cutaneous leishmaniasis. The studies examined the impact of the paromomycin has different characteristics and results. The aim of the present study was to conduct a systematic review and meta-analysis of all randomized clinical trials evaluating the effectiveness of paromomycin in the treatment of cutaneous leishmaniasis in Iran.

methodsLiterature search was conducted using MEDLINE, Web of Science, Scopus, Scientific Information Database, IranMedex, Magiran, Iranian Registry of Clinical Trials (from February 2000 to May 2016), and references cited in the text of selected studies. Search terms used were "paromomycin", "cutaneous leishmaniasis", "randomized"," aminosidine", "controlled trial", and "clinical trial". Random effects models were used to calculate the measure of association, with 95% confidence intervals, to analyze the efficacy of paromomycin in the treatment of cutaneous leishmaniasis.

resultsInitial search yielded 76 citations. Of these original results, 9 met our specific selection criteria. Four of the randomized controlled trials compared the efficacy of paromomycin in the treatment of cutaneous leishmaniasis with that of a placebo; they were included in the meta-analysis. The success rate of treatment with paromomycin was higher than that with the placebo (pooled RR=4.50, 95% CI: 2.54 to 8.02; P=0.001 and I

conclusionNo significant difference was observed between paromomycin and the other treatments in their effectiveness in the treatment of cutaneous leishmaniasis. Because no single drug is effective against all the forms of leishmaniasis, we suggest multidrug therapy.

Indexed as

Cutaneous leishmaniasisMeta-analysisParomomycin

Identifiers

PMID31182884
PMCPMC6525728
OpenAlexW2906370905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.